2002


2003


B Barlogie, R Kyle, K Anderson, P Greipp, H Lazarus, J Jacobson, E Rasmussen, J Cromer, J Crowley. Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 +


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=102326


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=104088

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2372


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=103729


LJ Goldstein, A O'Neill, JA Sparrano, EA Perez, LN Shulman, S Martino, AC Wolff, NE Davidson. LVEF

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=100450


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=103122


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=104048


http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T7X-49FGM43-51&_user=99318&_coverDate=10%2F01%2F2003&_alid=816267094&_rdoc=269&_fmt=high&_orig=search&_cdi=5070&_st=138&_docanchor=&view=c&_ct=790&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=baf5622b09460ade7ee6547f4b09492

JJ Lee, ES Kim, FR Khuri, RM Chamberlain, L Feng, B Williams, K Fu, J Cooper, SM Lippman, WK Hong. Longterm adherence, toxicity, and dose-intensity in a head and neck chemoprevention trial. Proc of the
Program Director/Principal Investigator (Last, First, Middle): Baker, Laurence H., D.O.

[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstra
ctID=103825](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstra
ctID=103825)


[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstra
ctID=104055](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstra
ctID=104055)


GA Omura, MF Brady, KY Look, HE Averette, JE Delmore, HJ Long, S Wadler, G Spiegel, SG Arbuck. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an inter-group study Journal of Clinical Oncology, 21(15):2843-2848, 2003. PMID: 12807937


[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstra
ctID=104215](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstra
ctID=104215)


DL Stirewalt, FR Appelbaum, CL Willman, RA Zager, DE Banker. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leukemia Research, 27:133-145, 2003. PMID: 12526919


2004


DT Blumenthal, M Quezado, M Santi, A Rapkiewicz, R Ronchetti, EJ Rushing. Prognostic value of epidermal growth factor receptor expression and small cell phenotype in patients with glioblastoma treated with induction

http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/4505?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=pauler&searchid=1&FIRSTINDEX=0&volume=22&issue=14_suppl&resourcetype=HWCIT


http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/539?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=fonseca&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT

http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/5202?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=barlogie&searchid=1&FIRSTINDEX=20&volume=104&issue=11&resourcetype=HWCIT


http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/701?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=dave&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT


PJ Hesketh, K Chansky, DH Lau, J Crowley, DR Gandara. Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age ≥ 70, or with performance status (PS) 2: a SWOG phase II trial (S0027). Proc of the American Society of Clinical Oncology, 23:627 (#7056), 2004. 

M Hussain, J Faulkner, U Vaishampayan, P Lara, D Petrylak, D Colevas, W Sakr, ED Crawford. Epothilone
B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). a Southwest Oncology up study (S0111). Proc of the American Society of Clinical Oncology, 23:383 (#4510), 2004. http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/4510?maxtoshow=&HITS=10&hits=10&RESULTFORM AT=&fulltext=hussain&searchid=1&FIRSTINDEX=0&volume=22&issue=14_suppl&resourceType=HWCIT


HO Smith, C Jiang, GR Weiss, AV Hallum III, PY Liu, AM Miller, DR Gandara, M Markman, DS Alberts. Tirapazamine plus cisplatin in advanced or recurrent squamous or adenosquamous carcinoma of the uterine cervix: a phase II study of the Southwest Oncology Group (SWOG). *Gynecologic Oncology*, 92:416 (#49), 2004. [http://www.sciencedirect.com/science?_ob=PublicationURL&_cdo=1&_cdi=6814&_user=9318&md5=74f1708f66e7a96f778a7115b4fd0ed0](http://www.sciencedirect.com/science?_ob=PublicationURL&_cdo=1&_cdi=6814&_user=9318&md5=74f1708f66e7a96f778a7115b4fd0ed0)


2005


ML Citron, DA Berry C Cirrincione, RB Livingston, W Gradishar, E Perez, H Muss, L Norton, E Winer, C Hudis. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less (DD) treatment: update by CALGB on breast cancer intergroup trial C9741 with ECOG, SWOG, & NCTCG. Proc of the American Society of Clinical Oncology, *Journal of Clinical Oncology*, 23(16S):33s (#620), 2005.


NE Davidson, AM O'Neill, AM Vukov, CK Osborne, S Martino, DR White, MD Abeloff. Chemoeendocrine therapy for premenopausal women with axillary lymph node positive, steroid hormone receptor-positive breast cancer.


DR Gandara, E Vallieres, LE Gaspar, K Kelly, KS Albain, RS Herbst Jr, PN Lara Jr, P Mack, PH Gumerlock,


http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/4556?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=hayden&searchid=1&FIRSTINDEX=0&volume=23&issue=16_suppl&resourceType=HWCIT


MA Hussein, J McCoy, A Jakubowiak, BG Durie, JJ Crowley, B Barlogie. SWOG 0204; phase 2 trial of thalidomide (T) + dexamethasone (D) induction followed by tandem autotransplant (TAT) and prednisone (P) + T maintenance for multiple myeloma (MM). Blood, (ASH Annual Meeting Abstracts) 106(11): #1169, 2005

LF Hutchins, SJ Green, PM Ravdin, D Lew, S Martino, M Abeloff, AP Lyss, C Allred, SE Rivkin, CK Osborne. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, methotrexate, and fluorouracil.


KCMJ Peters, SA Hundahl, EK Kranenbarg, H Hartgrink, C Van de Velde. Low maruyama index


E Vallieres, KMW Pisters, J Crowley, K Chansky, P Bunn, D Gandara. S9900: Preliminary “surgical” r


2006

http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/9518?maxtoshow=&HITS=10&hits=10&RESULTFORM AT=&fulltext=albritton&searchid=1&FIRSTINDEX=0&volume=24&issue=18_suppl&resourcetype=HWCIT


http://www.springerlink.com/content/y81136417955451w/fulltext.pdf


http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/1512?maxtoshow=&HITS=10&hits=10&RESULTFORM AT=&fulltext=blumenthal&searchid=1&FIRSTINDEX=0&volume=24&issue=18_suppl&resourcetype=HWCIT


GK Ellis, SJ Green, CA Russell, ME Royce, EA Perez, RB Livingston. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology, 24(18S):#LBA537, 2006. http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/LBA537?maxtoshow=&HITS=10&hits=10&RESULTFORMAT AT=&fulltext=ellis&searchid=1&FIRSTINDEX=0&volume=24&issue=18_suppl&resourcetype=HWCIT


S Iqbal, S McCoy, HJ Lenz, SE Rivkin, JN Atkins, CD Blanke. SWOG S0202 a phase II trial of gemcitabine and capcitabine in patients (pts) with unresectable or metastatic gall bladder cancer or cholangiocarcinoma. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology, 24(18S):#4134, 2006. http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/4134?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=iqbal&searchid=1&FIRSTINDEX=0&volume=24&issue=18_suppl&resourcetype=HWCIT


PC Mack, MW Redman, K Chansky, SK Williamson, N Farneth, PN Lara, Q Le, PH Gumerlock, JJ Crowley,

M Markman, PY Liu, S Wilczynski, B Monk, LJ Copeland, D Alberts. Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG 9701/GOG178: 12 versus (v) 3 cycles (c) of monthly single-agent paclitaxel (PAC) following attainment of a clinically –defined complete response (CR) to platinum (PLAT)/PAC. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology, 24(18S):#5005, 2006. http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/5005?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=markman&searchid=1&FIRSTINDEX=0&volume=24&issue=18_suppl&resourcetype=HWCIT


PL Porter, WE Barlow, IT Yeh, MG Lin, XP Yuan, E Donato, GW Sledge, CL: Shapiro, JN Ingle, CM Haskell, KS Albain, JM Roberts, RB Livingston, DF Hayes. p27Kip1 and cyclin E expression and breast cancer with adjuvant chemotherapy. Journal of the National Cancer Institute, 98(23):1723-1731, 2006. PMID: 17148774


http://meeting.asccp.org/cgi/content/abstract/24/18_suppl/407?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=regine&searchid=1&FIRSTINDEX=0&volume=24&issue=18_supp&resourceType=HWCIT


http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/809?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=roberts&searchid=1&FIRSTINDEX=10&volume=108&issue=11&resourceType=HWCIT


http://meeting.asccp.org/cgi/content/abstract/24/18_suppl/4525?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=cw+ryan&searchid=1&FIRSTINDEX=10&volume=24&issue=18_supp&resourceType=HWCIT


VK Sondak, MS Sable, JJ Mule. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clinical Cancer Research, 12(7 Suppl):2337s-2341s, 2006. PMID: 16609055


RP Whitehead, S McCoy, IS Wollner, L Wong, WG Harker, PM Hoff, PJ Gold, KG Billingsley, CD Blanke. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology, 24(18S):#3598, 2006. http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/3598?maxtoshow=&HITS=10&hits=10&RESULTFORM AT=&fulltext=whitehead&searchid=1&FIRSTINDEX=0&volume=24&issue=18_suppl&resourcetype=HWCIT

RP Whitehead, S McCoy, IS Wollner, L Wong, WG Harker, CD Blanke. Phase II trial of depsipeptide (NSC 30176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group trial. American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, #255, 2006. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&co nfiD=41&abstractID=139


2007


SS Badve, FL Baehner, R Gray, B Childs, T Maddala, S Rowley, S Shakt, N Davidson, LJ Goldstein,
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32667

http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/520?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&author1=Bernstein%2C+SH&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&andsearchid=1&FIRSTINDEX=20

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4647?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=chang&searchid=1&FIRSTINDEX=20&volume=25&issue=18_suppl&resourcetype=HWCIT


http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4639?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=rankin&searchid=1&FIRSTINDEX=0&volume=25&issue=18_suppl&resourcetype=HWCIT

http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/387?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&author1=epner&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&andsearchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=11/1/2007&resourcetype=HWCIT

http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/440?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&author1=Erba%2C+HP&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&andsearchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=11/1/2007&resourcetype=HWCIT


DR Gandara, T Kawaguchi, J Crowley, J Moon, M Kawahara, S Teramukai, S Williamson, K Furuse, HL Mcleod, PC Mack. Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced


PJ Hesketh, RC Lilienbaum, K Chansky, A Dowlati, P Graham, RA Chapman, JJ Crowley, DR


SA Hundahl, KCJM Peeters, EK Kranenbarg, H Hartgrink, CJH van de Velde. Improved regional control and survival with "low maruyama index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 trial. Gastric Cancer, 10(2):84-86, 2007. PMID: 17577616


L Kutteh, T Hobday, A Jaffe, B Laplante, D Hillman, P Kaufman, N Davidson, S Martino, E Perez. A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III


CW Ryan, BH Goldman, PN Lara Jr, PC Mack, TM Beer, CM Tangen, D Lemmon, CX Pan, HA Drabkin,


http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/10004?maxtoshow=&HITS=10&hits=10&RESULTFORMATAT=&fulltext=van+glabbeke&searchid=1&FIRSTINDEX=0&volume=25&issue=18_suppl&resourcetype=HWCIT

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/15562?maxtoshow=&HITS=10&hits=10&RESULTFORMATAT=&fulltext=van+veldhuizen&searchid=1&FIRSTINDEX=0&volume=25&issue=18_suppl&resourcetype=HWCIT


PMID:16798070

PMID: 17299095

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/6044?maxtoshow=&HITS=10&hits=10&RESULTFORMATAT=&fulltext=williamson&searchid=1&FIRSTINDEX=0&volume=25&issue=18_suppl&resourcetype=HWCIT

PMID: 17574960

PMID: 17881637

PMID: 17023574

2008


KS Albain, JM Unger, JJ Crowley, CA Coltman, Jr., FL Meyskens, DL Hershman. Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. Submitted to Journal of the National Cancer Institute, 2008; under revision 1/09.


DS Alberts, PY Liu, SP Wilczynski, MC Clouser, AM Lopez, DP Michelin, VJ Lanzotti, M Markman. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecologic Oncology, 108:90-94, 2008. PMID: 17949799


RW de Vere White, PN Lara, B Goldman, MC Tangen, DC Smith, DP Wood, MHA Hussain, ED Crawford. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group Trial (S0219). Submitted to Journal of Urology, 10/2/08; resubmitted with revisions 12/08.


M Hussain, B Goldman, C Tangen, C Higan, DP Petrylak, ED Crawford. Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. Journal of Clinical Oncology, 26(15S):253s, #5015, 2008.


ES Kim, RS Herbst, J Moon, J Crowley, M Redman, SR Dakhil, J Wade, K Kelly, DR Gandara. SWOG 0536: SWOG phase II trial of carboplatin (C), paclitaxel (P),Cetuximab (CX) and bevacizumab (B) followed by Cetuximab and bevacizumab in advanced non-small cell lung cancer (NSCLC). Presented at the 2008 annual meeting of the International Association for the Study of Lung Cancer; Journal of Thoracic Oncology, 3(11)supp 4:S266, abst. #9, 2008


SP Lerner, CM Tangen, H Sucharew, D Wood, ED Crawford. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of progression and death in patients with high risk non-muscle invasive bladder cancer. *Urologic Oncology*, 2008 Feb 22 [Epub ahead of print]  
PMID: 18367117

SP Lerner, JP Stein, WM Stadler, S Groshen, E Tuazon, DG Skinner, D Raghavan, D Esrig, G Steinberg, C Hall, R Cote. Results of the p53 targeted therapy trial for patients with organ confined node negative bladder cancer treated with radical cystectomy. Accepted for oral presentation at 2008 Annual Meeting of Society of Urological Oncology (December, 2008).


http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/3598?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=unger&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT


CM Moinpour, GW Donaldson, Y Nakamura. Chemo-therapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: dynamically modified outcomes analysis of a randomized controlled trial. Accepted by *Quality of Life Research*, 12/08.

SR Moore, DL Persons, JA Sosman, D Bobadilla, V Bedell, DD Smith, SR Wolman, RJ Tuthill, J Moon, VK Sondak, ML Slovak. Detection of copy number alterations in malignant melanoma by both a panel of 16 DNA FISH probes and array comparative genomic hybridization: a Southwest Oncology Group study (S9431).  

*Journal of Clinical Oncology*, 26(15s):400S, #7512, 2008


GP Swanson, I Thompson, C Tangen, J Paradelo, E Canby-Hagino, E Crawford, G Miller, M Lucia, J


GP Swanson, IM Thompson, C Tangen, J Paradelo, E Canby-Hagino, ED Crawford, G Miller, MS Lucia, J Forman, J Chin. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. ASTRO, Boston, MA, September, 2008; International Journal of Radiation Oncology Biology Physics, 72(1) suppl 1:S31, 2008. http://www.sciencedirect.com.libproxy.uthscsa.edu/science?_ob=ArticleURL&_udi=B6T7X-4T85W5M2R&_user=108488&_coverDate=09%2F01%2F2008&_alid=785532217&_rdoc=1&_fmt=high&_orig=search&_cdi=5070&_sort=d&docanchor=&view=c&ct=29&acct=C000059724&_version=1&_urlVersion=0&_userid=108488&md5=5cae9b1302e5a1e06e12146c78d74ea0


IM Thompson, CM Tangen, J Paradelo, MS Lucia, G Miller, D Troyer, E Messing, J Forman, J Chin, G Swanson, E Canby-Hagino and ED Crawford. Adjuvant radiotherapy for pathological T3N0M0 prostate Cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. Journal of Urology, in press, 12/08.


AD Tiersten, PY Liu, HO Smith, SP Wilczynski, WR Robinson, M Markman, DS Alberts. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group study S0009. Not accepted by Journal of Clinical Oncology; accepted by Gynecologic Oncology, 11/19/08.


R Tubbs, WE Barlow, GT Budd, E Swain, P Porter, A Gown, IT Yeh, G Sledge, S Shapiro, J Ingle, C Haskell, K Albain, R Livingston, DF Hayes. HER2 but not TOP2A gene amplification is associated (with response to adriamycin
based therapy: Southwest Oncology Group directed Intergroup Study S9313 (INT-0137). R Tubbs, WE Barlow, GT Budd, E Swain, P Porter, A Gown, IT Yeh, G Sledge, S Shapiro, J Ingle, C Haskell, K Albain, R Livingston, DF Hayes. Submitted to Journal of Clinical Oncology, 9/08; resubmitted with revisions 1/2/09.


W Zhang, CJ Rankin, F Nagashima, CM Ulrich, RS Holmes, KW Makar, JK Benedetti, CD Blanke, SR Smalley, HJ Lenz. Pharmacogenetic analysis of stage II/III rectal cancer patients treated with 5-Fluorouracil and pelvic radiation in...
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&conflID=53&abstactID=10495

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&conflID=55&abstactID=36278

IN PREPARATION (draft manuscript available, in circulation or under revision)


CA Coltman. Including the incorporation of new technology into data systems and communication: the Southwest Oncology Group progress in cancer research.


DP Petrylak et al. Phase II study of continuous infusion gallium nitrate in platinum-refractory urothelial tract tumors: a Southwest Oncology Group Study.

WE Samlowski, J Moon, RJ Tuthill, MC Heinrich, NB Haas, SA Merl, RC DeConti, JA Thompson, MT Witter, LE Flaherty, VK Sondak. A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group phase II study (S0331).

JA Sosman, J Moon, RJ Tuthill, JA Warneke, JY Vetto, BG Redman, PY Liu, JM Unger, LE Flaherty, Kodak. A Phase II Trial of Complete Surgical Resection for Stage IV Melanoma: Results of SWOG Clinical Trial S9430


L Wagner, M Wang, K Miller, NE Davidson, J Gralow, M Dickler, M Cobleigh, E Perez, T Shenker, D Cella. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab (rumba QOL for VEGF) as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100).